Cargando…
Full-length versus intact PTH concentrations in pseudohypoparathyroidism type 1 and primary hyperparathyroidism: clinical evaluation of immunoassays in individuals from China
PURPOSE: The application of the third-generation parathyroid hormone (PTH) assay [PTH(1–84) assay] for evaluating PTH levels in patients with pseudohypoparathyroidism type-1 (PHP1) is less popular than the second-generation assay. Therefore, we aimed at examining the conformity between the PTH(1–84)...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553086/ https://www.ncbi.nlm.nih.gov/pubmed/36220966 http://dx.doi.org/10.1007/s12020-022-03204-7 |
_version_ | 1784806391574167552 |
---|---|
author | Yang, Yi Song, Ailing Song, An Hu, Yingying Jiang, Yan Li, Mei Xia, Weibo Xing, Xiaoping Cheng, Xinqi Wang, Ou |
author_facet | Yang, Yi Song, Ailing Song, An Hu, Yingying Jiang, Yan Li, Mei Xia, Weibo Xing, Xiaoping Cheng, Xinqi Wang, Ou |
author_sort | Yang, Yi |
collection | PubMed |
description | PURPOSE: The application of the third-generation parathyroid hormone (PTH) assay [PTH(1–84) assay] for evaluating PTH levels in patients with pseudohypoparathyroidism type-1 (PHP1) is less popular than the second-generation assay. Therefore, we aimed at examining the conformity between the PTH(1–84) assay and the intact PTH (iPTH) assay, specifically examining their performance in individuals with PHP1 versus individuals with primary hyperparathyroidism (PHPT), compared to healthy controls. METHODS: PTH(1–84) and iPTH assay were performed in patients with PHP1, patients with PHPT, and healthy volunteers. ∆PTH%, PTH(1–84)/iPTH (3(rd)/2(nd) ratio), iPTH/upper limit of normal (ULN), and PTH (1–84)/ULN of each group were calculated for comparison. Linear regression, Kappa conformity test, and Bland–Altman analysis of ∆PTH/mean of iPTH and PTH(1–84) (percent bias) plotted against the mean of iPTH and PTH(1–84) were performed to determine the conformance of PTH(1–84) assay with iPTH assay. RESULTS: A total of 54 patients with PHP1, 127 patients with PHPT, and 65 healthy volunteers were enrolled in this study. All the three groups showed strong linear relationship between iPTH and PTH (1–84) (r(2) = 0.9661, 0.7733, and 0.9575, respectively). No significant differences were noted in 3(rd)/2(nd) ratio (median 0.76 vs. 0.72) between the PHP1 and PHPT groups (p > 0.05). Conformity examination showed the Kappa value was 0.778 and 0.395 for PHP1 and PHPT groups respectively. No difference in the Kappa values was found between PHP1A and PHP1B subgroups. Bland–Altman plot demonstrated that the proportion of data points that were plotted within mean ± 1.96 SD in PHP1, PHPT and normal control groups were 96.3%, 93.7%, and 98.5%, respectively. The mean percent bias of the three groups were 26.1%, 31.2%, and 17.0%, respectively. The range of mean ± 1.96 SD of percent bias of the three groups were 2.2%–50.0%, −14.3%–76.6%, and 6.7%–27.2%, respectively. CONCLUSION: Although iPTH and PTH(1–84) values were both lower in the present PHP1 cohort than in the PHPT cohort, there appear to be differences in the relative agreement between both immunoassays, and in the relationship between the two values, especially in comparison to healthy controls. Whether these differences are due to differential accumulation of C-terminal fragments or other factors requires further study. |
format | Online Article Text |
id | pubmed-9553086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-95530862022-10-12 Full-length versus intact PTH concentrations in pseudohypoparathyroidism type 1 and primary hyperparathyroidism: clinical evaluation of immunoassays in individuals from China Yang, Yi Song, Ailing Song, An Hu, Yingying Jiang, Yan Li, Mei Xia, Weibo Xing, Xiaoping Cheng, Xinqi Wang, Ou Endocrine Original Article PURPOSE: The application of the third-generation parathyroid hormone (PTH) assay [PTH(1–84) assay] for evaluating PTH levels in patients with pseudohypoparathyroidism type-1 (PHP1) is less popular than the second-generation assay. Therefore, we aimed at examining the conformity between the PTH(1–84) assay and the intact PTH (iPTH) assay, specifically examining their performance in individuals with PHP1 versus individuals with primary hyperparathyroidism (PHPT), compared to healthy controls. METHODS: PTH(1–84) and iPTH assay were performed in patients with PHP1, patients with PHPT, and healthy volunteers. ∆PTH%, PTH(1–84)/iPTH (3(rd)/2(nd) ratio), iPTH/upper limit of normal (ULN), and PTH (1–84)/ULN of each group were calculated for comparison. Linear regression, Kappa conformity test, and Bland–Altman analysis of ∆PTH/mean of iPTH and PTH(1–84) (percent bias) plotted against the mean of iPTH and PTH(1–84) were performed to determine the conformance of PTH(1–84) assay with iPTH assay. RESULTS: A total of 54 patients with PHP1, 127 patients with PHPT, and 65 healthy volunteers were enrolled in this study. All the three groups showed strong linear relationship between iPTH and PTH (1–84) (r(2) = 0.9661, 0.7733, and 0.9575, respectively). No significant differences were noted in 3(rd)/2(nd) ratio (median 0.76 vs. 0.72) between the PHP1 and PHPT groups (p > 0.05). Conformity examination showed the Kappa value was 0.778 and 0.395 for PHP1 and PHPT groups respectively. No difference in the Kappa values was found between PHP1A and PHP1B subgroups. Bland–Altman plot demonstrated that the proportion of data points that were plotted within mean ± 1.96 SD in PHP1, PHPT and normal control groups were 96.3%, 93.7%, and 98.5%, respectively. The mean percent bias of the three groups were 26.1%, 31.2%, and 17.0%, respectively. The range of mean ± 1.96 SD of percent bias of the three groups were 2.2%–50.0%, −14.3%–76.6%, and 6.7%–27.2%, respectively. CONCLUSION: Although iPTH and PTH(1–84) values were both lower in the present PHP1 cohort than in the PHPT cohort, there appear to be differences in the relative agreement between both immunoassays, and in the relationship between the two values, especially in comparison to healthy controls. Whether these differences are due to differential accumulation of C-terminal fragments or other factors requires further study. Springer US 2022-10-11 2022 /pmc/articles/PMC9553086/ /pubmed/36220966 http://dx.doi.org/10.1007/s12020-022-03204-7 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Article Yang, Yi Song, Ailing Song, An Hu, Yingying Jiang, Yan Li, Mei Xia, Weibo Xing, Xiaoping Cheng, Xinqi Wang, Ou Full-length versus intact PTH concentrations in pseudohypoparathyroidism type 1 and primary hyperparathyroidism: clinical evaluation of immunoassays in individuals from China |
title | Full-length versus intact PTH concentrations in pseudohypoparathyroidism type 1 and primary hyperparathyroidism: clinical evaluation of immunoassays in individuals from China |
title_full | Full-length versus intact PTH concentrations in pseudohypoparathyroidism type 1 and primary hyperparathyroidism: clinical evaluation of immunoassays in individuals from China |
title_fullStr | Full-length versus intact PTH concentrations in pseudohypoparathyroidism type 1 and primary hyperparathyroidism: clinical evaluation of immunoassays in individuals from China |
title_full_unstemmed | Full-length versus intact PTH concentrations in pseudohypoparathyroidism type 1 and primary hyperparathyroidism: clinical evaluation of immunoassays in individuals from China |
title_short | Full-length versus intact PTH concentrations in pseudohypoparathyroidism type 1 and primary hyperparathyroidism: clinical evaluation of immunoassays in individuals from China |
title_sort | full-length versus intact pth concentrations in pseudohypoparathyroidism type 1 and primary hyperparathyroidism: clinical evaluation of immunoassays in individuals from china |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553086/ https://www.ncbi.nlm.nih.gov/pubmed/36220966 http://dx.doi.org/10.1007/s12020-022-03204-7 |
work_keys_str_mv | AT yangyi fulllengthversusintactpthconcentrationsinpseudohypoparathyroidismtype1andprimaryhyperparathyroidismclinicalevaluationofimmunoassaysinindividualsfromchina AT songailing fulllengthversusintactpthconcentrationsinpseudohypoparathyroidismtype1andprimaryhyperparathyroidismclinicalevaluationofimmunoassaysinindividualsfromchina AT songan fulllengthversusintactpthconcentrationsinpseudohypoparathyroidismtype1andprimaryhyperparathyroidismclinicalevaluationofimmunoassaysinindividualsfromchina AT huyingying fulllengthversusintactpthconcentrationsinpseudohypoparathyroidismtype1andprimaryhyperparathyroidismclinicalevaluationofimmunoassaysinindividualsfromchina AT jiangyan fulllengthversusintactpthconcentrationsinpseudohypoparathyroidismtype1andprimaryhyperparathyroidismclinicalevaluationofimmunoassaysinindividualsfromchina AT limei fulllengthversusintactpthconcentrationsinpseudohypoparathyroidismtype1andprimaryhyperparathyroidismclinicalevaluationofimmunoassaysinindividualsfromchina AT xiaweibo fulllengthversusintactpthconcentrationsinpseudohypoparathyroidismtype1andprimaryhyperparathyroidismclinicalevaluationofimmunoassaysinindividualsfromchina AT xingxiaoping fulllengthversusintactpthconcentrationsinpseudohypoparathyroidismtype1andprimaryhyperparathyroidismclinicalevaluationofimmunoassaysinindividualsfromchina AT chengxinqi fulllengthversusintactpthconcentrationsinpseudohypoparathyroidismtype1andprimaryhyperparathyroidismclinicalevaluationofimmunoassaysinindividualsfromchina AT wangou fulllengthversusintactpthconcentrationsinpseudohypoparathyroidismtype1andprimaryhyperparathyroidismclinicalevaluationofimmunoassaysinindividualsfromchina |